Listing 1 - 6 of 6 |
Sort by
|
Choose an application
Thrombotic disorders of the circulatory system represent the leading cause of morbidity, mortality, and health care expenditure in the United States. The Second Edition of Fibrinolytic and Antithrombotic Therapy provides a practical, evidence-based approach to the managment of thrombotic disorders for all clinicians involved in the care of patients with these disorders. It provides not only vital conceptual information on fibrinolytic and antithrombotic therapy, but also the means to apply it to everyday decision making and patient care. Focusing on management guidelines and critical pathways, the text stresses practicality and usability. It will be a valuable resource for the wide range of clinicians involved in the care of patients with these disorders.
Thrombolytic therapy. --- Fibrinolytic agents. --- Thrombosis --- Blood --- Cardiovascular system --- Protein C deficiency --- Protein S deficiency --- Antithrombotic agents --- Antithrombotics --- Fibrinolytic enzymes --- Fibrinolytics --- Thrombolytic agents --- Thrombolytics --- Enzymes --- Hematologic agents --- Fibrinolytic therapy --- Thrombolysis --- Chemotherapy --- Fibrinolysis --- Treatment. --- Coagulation --- Diseases
Choose an application
Stroke is the most common cause of adult mortality in the United States. Antithrombotic agents form the mainstay of stroke prevention. Aspirin produces a modest reduction in the risk of second stroke and transient ischemic attack (TIA, mini-stroke) and is widely recommended for initial therapy. The thienopyridines (Ticlid) and clopodogrel (Plavix) are alternatives for secondary prevention in patients who do not respond to or cannot take aspirin. They are no more effective than aspirin and have been associated with thrombotic thrombocytopenic purpura. The combination of aspirin and extended-rel
Transient ischemic attack --- Fibrinolytic agents. --- Antithrombotic agents --- Antithrombotics --- Fibrinolytic enzymes --- Fibrinolytics --- Thrombolytic agents --- Thrombolytics --- Enzymes --- Hematologic agents --- Ischemic attack, Transient --- Mini-stroke --- TIA (Transient ischemic attack) --- Cerebral ischemia --- Chemotherapy. --- Prevention.
Choose an application
Substantial morbidity and mortality remains associated with thrombotic events has stimulated the rapid expansion of the available armamentarium to combat pathologic thrombosis. Pathologic thrombosis plays an essential role in the pathogenesis of acute coronary syndromes (ACS), ischemic complications of percutaneous coronary intervention (PCI), venous thromboembolic disease, and embolic complications of arrhythmias and various cardiomyopathies. Written by experts in the field, Antithrombotic Drug Therapy in Cardiovascular Disease carefully examines individual and various combinations of the available antithrombotic regimens including fibrinolytic agents, antiplatelet therapies (aspirin, thieneopyridines, glycoprotein IIb/IIIa inhibitors), and anticogulant therapies (unfractionated heparin, low-molecular-weight heparins, direct thrombin inhibitors, and synthetic factor X inhibitors), non-ST-segment elevation (NSTE) ACS and ST-segment elevation myocardial infarction (STEMI). A detailed overview, Antithrombotic Drug Therapy in Cardiovascular Disease presents the evidence demonstrating the efficacy of available antithrombotic therapies in specific disease states such as atrial fibrillation, cardiomyopathy, valvular heart disease, and heparin-induced thrombocytopenia (HIT).
Cardiovascular system -- Diseases -- Chemotherapy. --- Fibrinolytic agents. --- Thrombolytic therapy --- Cardiovascular system --- Fibrinolytic agents --- Cardiovascular Diseases --- Fibrinolytic Agents --- Thrombolytic Therapy --- Hematologic Agents --- Fibrin Modulating Agents --- Drug Therapy --- Diseases --- Cardiovascular Agents --- Therapeutics --- Therapeutic Uses --- Molecular Mechanisms of Pharmacological Action --- Pharmacologic Actions --- Analytical, Diagnostic and Therapeutic Techniques and Equipment --- Chemical Actions and Uses --- Chemicals and Drugs --- Pharmacy, Therapeutics, & Pharmacology --- Health & Biological Sciences --- Medicine --- Chemotherapy --- Chemotherapy. --- Circulatory system --- Vascular system --- Antithrombotic agents --- Antithrombotics --- Fibrinolytic enzymes --- Fibrinolytics --- Thrombolytic agents --- Thrombolytics --- Medicine. --- Interventional radiology. --- Internal medicine. --- Cardiology. --- Vascular surgery. --- Medicine & Public Health. --- Internal Medicine. --- Interventional Radiology. --- Vascular Surgery. --- Vascular surgery --- Heart --- Internal medicine --- Medicine, Internal --- Radiology, Interventional --- Medical radiology --- Clinical sciences --- Medical profession --- Human biology --- Life sciences --- Medical sciences --- Pathology --- Physicians --- Blood --- Enzymes --- Hematologic agents --- Circulation --- Interventional radiology . --- Blood-vessels --- Surgery.
Choose an application
Stress, high blood pressure, smoking, pollution, fast foods, overweight, excessive travelling, surgery, less movement are common features in our modern life. These features are risky for blood clotting disorders. According to WHO, over 29% of the total mortalities worldwide are due to thrombosis. By the year, 2020 cardiovascular diseases (CVDs) may cause an estimated 25 million deaths per year, thus antithrombotic therapy is of great interest. The available thrombolytic agents such as urokinase are highly expensive, antigenic, quite unspecific, pyretogenic and hemorrhagenic. Therefore, the production of fibrinolysing enzymes, which rapidly dissolute thrombi within the vascular tree, without the detriments by microorganisms, as described in this book, is the desirable aim of today’s research.
Fibrinolytic agents. --- Fibrinolytic agents --- Organisms --- Fibrin Modulating Agents --- Endopeptidases --- Hematologic Agents --- Plasminogen Activators --- Cardiovascular Agents --- Blood Coagulation Factors --- Therapeutic Uses --- Molecular Mechanisms of Pharmacological Action --- Peptide Hydrolases --- Pharmacologic Actions --- Blood Proteins --- Hydrolases --- Chemical Actions and Uses --- Enzymes --- Proteins --- Chemicals and Drugs --- Enzymes and Coenzymes --- Amino Acids, Peptides, and Proteins --- Fibrinolytic Agents --- Streptokinase --- Bacteria --- Health & Biological Sciences --- Biology --- Pharmacy, Therapeutics, & Pharmacology --- Microbiology & Immunology --- Thrombosis. --- Anticoagulants (Medicine) --- Antithrombotic agents --- Blood thinners --- Blood thinning drugs --- Antithrombotics --- Fibrinolytic enzymes --- Fibrinolytics --- Thrombolytic agents --- Thrombolytics --- Medicine. --- Human physiology. --- Medical microbiology. --- Cardiology. --- Hematology. --- Biomedicine. --- Medical Microbiology. --- Human Physiology. --- Haematology --- Internal medicine --- Blood --- Heart --- Human biology --- Medical sciences --- Physiology --- Human body --- Clinical sciences --- Medical profession --- Life sciences --- Pathology --- Physicians --- Diseases --- Hematologic agents --- Cardiovascular system --- Protein C deficiency --- Protein S deficiency --- Coagulation --- Microbiology. --- Microbial biology --- Microorganisms
Choose an application
Thromboembolism in Orthopedic Surgery reviews the main topics in thromboprophylaxis around orthopedic surgery, from a general view of the problems with the disease and highlighting them in orthopedics to the new specific protocols involving, for example, new oral anticoagulants. The wide scope of this book covers topics ranging from The prevalence of the venous thromboembolism in each procedure and the risk factors to bear in mind in each one. The diagnosis and treatment of venous thromboembolism. The methods for thromboprophylaxis. Anaesthetic implications for thromboprophylaxis and, also, main implications of the application of antithrombotic protocols in the anaesthetic practice are covered. An approach based on dividing the orthopedic procedures according to their own thrombotic risk was used, thus providing separate protocols for each thromboprophylaxis: high risk, day surgery procedures and “special” surgical procedures. Finally, we review the problems involving the perioperatory management of antiaggregated and anticoagulated patients, with a special part in hip fracture surgery. The multidisciplinary approach and contributions from a panel of expert international authors have come together to create an excellent teaching resource, and essential guide to improving the application of thromboprophylaxis in orthopedic surgery.
Blood -- Coagulation. --- Fibrinolytic agents. --- Orthopedic surgery. --- Thrombosis. --- Thromboembolism --- Orthopedic surgery --- Fibrin Modulating Agents --- Embolism and Thrombosis --- Surgical Procedures, Operative --- Hematologic Agents --- Therapeutics --- Thrombosis --- Cardiovascular Agents --- Therapeutic Uses --- Analytical, Diagnostic and Therapeutic Techniques and Equipment --- Molecular Mechanisms of Pharmacological Action --- Vascular Diseases --- Pharmacologic Actions --- Cardiovascular Diseases --- Chemical Actions and Uses --- Diseases --- Chemicals and Drugs --- Fibrinolytic Agents --- Orthopedic Procedures --- Medicine --- Surgery & Anesthesiology --- Health & Biological Sciences --- Pathology --- Surgery - General and By Type --- Complications --- Thromboembolism. --- Operative orthopedics --- Medicine. --- Hematology. --- Orthopedics. --- Medicine & Public Health. --- Orthopedics --- Surgery, Operative --- Embolism --- Orthopaedics --- Orthopedia --- Surgery --- Haematology --- Internal medicine --- Blood
Choose an application
Without warning stroke can paralyze, blind, or kill. Some victims recover, but many do not and may even suffer another disabling or fatal attack. The drug known as tPA can drastically reduce the long-term disability associated with stroke, but despite its near-miraculous capabilities and the growing support of most neurologists, it has been slow to win acceptance as the standard of care in emergency departments nationwide. tPA for Stroke chronicles how this remarkable drug came to be tested in stroke victims, its early years in development by the pharmaceutical giant Genentech, and its eventua
Cerebrovascular disease --- Tissue plasminogen activator --- Activator, Tissue plasminogen --- Plasminogen activator, Tissue-type --- Tissue-type plasminogen activator --- TPA (Biochemistry) --- Circulating anticoagulants --- Endothelium --- Plasminogen activators --- Apoplexy --- Brain --- Cerebral circulation disorders --- Cerebral vascular accident --- Cerebrovascular accident --- Cerebrovascular disorders --- Cerebrovascular syndrome --- CVA (Disease) --- Stroke --- Neglect (Neurology) --- Chemotherapy --- History. --- Therapeutic use --- Blood-vessels --- Diseases --- Fibrinolytic Agents --- Tissue Plasminogen Activator --- Therapeutic use. --- Drug therapy.
Listing 1 - 6 of 6 |
Sort by
|